Home > Healthcare > Drug Device Combination > Drug Filled Devices > U.S. Hormone Replacement Therapy Market

U.S. Hormone Replacement Therapy Market Trends

Report ID: GMI7407
Published Date: Nov 2023
Report Format: PDF

Download Free Sample

U.S. Hormone Replacement Therapy Market Trends

The rising prevalence of hormonal disorders serves as a compelling driver for the increased adoption of hormone replacement therapy (HRT). As societies age and lifestyles evolve, there has been a noticeable uptick in the incidence of hormonal imbalances, particularly among the elderly population.

Conditions such as menopause in women and andropause in men, coupled with disorders like hypothyroidism and adrenal insufficiency, contribute to a growing demand for effective hormonal management.
For instance, according to National Institute of Health (NIH), nearly one in 4,000 to 6,000 children and about 50,000 adults suffer from growth hormone deficiency in the U.S. This demographic shift, alongside heightened awareness and diagnostics, propels the need for therapeutic interventions like HRT to restore hormonal equilibrium and enhance the quality of life for those affected.

Technological advancements in drug delivery methods have played a pivotal role in driving the hormone replacement therapy (HRT) industry, leading to improved patient adherence, convenience, and treatment outcomes.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

U.S. hormone replacement therapy industry size was USD 6.9 billion in 2022 and is anticipated to be valued at USD 13.4 billion from 2023-2032 due to the aging population and the significant number of women reaching menopausal stages.

The oral route of administration recorded 43.5% share of the market in 2022 driven by non-invasive nature, precise and consistent drug dosing, affordability, and the strong preference of patients.

The hospital pharmacies distribution channel segment held 57.2% of the U.S. hormone replacement therapy market share in 2022 due to the presence of the highest quality of care.

Some of the major hormone replacement therapy firms in the U.S. include Eli Lilly and Company, Bayer AG, Pfizer Inc., Viatris, Inc., Noven Pharmaceuticals, Inc., Merck KGaA, Novo Nordisk A/S, and F. Hoffmann-La Roche Ltd.